Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area

    Biotech

    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more

    eHealth

    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more

    Healthcare

    The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

    Read more

    Pharmaceuticals

    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary

    Feed

    Show only
    Marite Aragaki
    Dec 2018
    CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
    13/09/2019
    SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
    Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s dar­unavir product (case C-114/18).
    03/09/2019
    NICE draft re­com­mend­a­tions on medi­cin­al can­nabis
    On 8 Au­gust 2019, the Na­tion­al In­sti­tute for Health & Care Ex­cel­lence (NICE) pub­lished draft guid­ance on pre­scrib­ing can­nabis-based medi­cin­al products for con­sulta­tion (Guid­ance). The Guid­ance will re­place in­ter­im clin­ic­al guid­ance is­sued by spe­cial­ist med­ic­al.
    18/06/2019
    Is an in­tel­li­gent AI tool right for your busi­ness?
    The Na­tion­al Cy­ber Se­cur­ity Centre has re­cently re­leased guid­ance on as­sess­ing in­tel­li­gent tools for cy­ber se­cur­ity (avail­able here). This guid­ance provides a valu­able op­por­tun­ity for busi­nesses of any size to re­flect on how they should (or equally, should.
    13/06/2019
    SPC Man­u­fac­tur­ing Waiver to come in­to ef­fect 1 Ju­ly 2019
    Gen­er­ics com­pan­ies will soon be able to man­u­fac­ture SPC-pro­tec­ted drugs for ex­port out­side the EU un­der new man­u­fac­tur­ing waiver pro­vi­sions. In the last six months of the SPC life­time, it will also be al­low­able to man­u­fac­ture gen­er­ics for stock­pil­ing for “day.
    06/06/2019
    The Bribery Act 2010 in Scot­land: where are we now?
    De­scribed earli­er this year by the House of Lords Se­lect Com­mit­tee as hav­ing cre­ated “an in­ter­na­tion­al gold stand­ard for anti-bribery and cor­rup­tion le­gis­la­tion”, the com­ing month will mark the eight year an­niversary of the Bribery Act 2010 com­ing in­to force.
    30/05/2019
    EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from...
    The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc. 's European pat­ent ap­plic­a­tion (EP07837908. 8), the claimed chem­ic­al en­tity did not qual­i­fy as a 'sub­stance or com­pos­i­tion'.
    15/05/2019
    The Broad In­sti­tute’s CR­IS­PR Pat­ent Ap­peal at the EPO
    The Broad In­sti­tute of MIT and Har­vard owns sev­er­al key pat­ents re­lated to the CR­IS­PR tech­no­logy. One such pat­ent is EP2771468 (“EP ‘468”), which relates to a fun­da­ment­al as­pect of the CR­IS­PR tech­no­logy in eu­k­a­ryot­ic cells.
    10/05/2019
    Uni­versity ordered to dis­close chil­dren’s clin­ic­al tri­al data 
    In The Uni­versity of Bris­tol v John Peters and The In­form­a­tion Com­mis­sion­er EA/2018/0142, the First-Tier Tribunal held that an­onymised clin­ic­al tri­al data is not ex­empt from dis­clos­ure un­der The Free­dom of In­form­a­tion Act 2000 (FOIA).
    27/03/2019
    Judg­ment on Ab­rax­is C-443/17; 21st March 2019
    The CJEU de­livered its judg­ment last week on the case of Ab­rax­is v Comp­troller Gen­er­al of Pat­ents con­cern­ing Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ates (SPCs) for new for­mu­la­tions of medi­cin­al products. The Court has ruled that Art­icle 3(d) of Reg­u­la­tion No 469/2009,.
    11/03/2019
    Pro­gress on the Life Sci­ences Sec­tor Deal 2
    The Of­fice for Life Sci­ences has pub­lished its Feb­ru­ary edi­tion of the Life Sci­ences In­dus­tri­al Strategy & Sec­tor Deal News­let­ter (the “News­let­ter”). The News­let­ter provides an up­date on how the strategy has pro­gressed since phase 2of the Life Sci­ences Sec­tor.
    26/02/2019
    Valid­ity of pat­ent con­sidered at pre­lim­in­ary in­junc­tion stage
    1. In­tro­duc­tion In a re­cent judg­ment, the High Court con­sidered the valid­ity of a pat­ent at the pre­lim­in­ary in­junc­tion stage, on the basis of a sum­mary judg­ment ap­plic­a­tion brought by Dr Reddy’s Labor­at­or­ies (UK) Lim­ited (“DRL”), a gen­er­ic phar­ma­ceut­ic­al com­pany.